JMKX001899
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for JMKX001899, covering 2024-06-25 to 2025-11-21. Get the full timeline:
Most recent: Clinical Trial Update: Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC [Phase 3]